- Home
- OKE vs TNGX Comparison
OKE vs TNGX Comparison
Compare OKE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKE
- TNGX
- Stock Information
- Founded
- OKE 1906
- TNGX 2014
- Country
- OKE United States
- TNGX United States
- Employees
- OKE N/A
- TNGX N/A
- Industry
- OKE Oil & Gas Production
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- OKE Utilities
- TNGX Health Care
- Exchange
- OKE Nasdaq
- TNGX Nasdaq
- Market Cap
- OKE 54.9B
- TNGX 351.2M
- IPO Year
- OKE N/A
- TNGX N/A
- Fundamental
- Price
- OKE $81.40
- TNGX $5.87
- Analyst Decision
- OKE Buy
- TNGX Strong Buy
- Analyst Count
- OKE 14
- TNGX 6
- Target Price
- OKE $103.43
- TNGX $12.20
- AVG Volume (30 Days)
- OKE 3.9M
- TNGX 2.9M
- Earning Date
- OKE 08-04-2025
- TNGX 08-06-2025
- Dividend Yield
- OKE 5.05%
- TNGX N/A
- EPS Growth
- OKE 18.10
- TNGX N/A
- EPS
- OKE 5.11
- TNGX N/A
- Revenue
- OKE $24,960,000,000.00
- TNGX $40,990,000.00
- Revenue This Year
- OKE $29.67
- TNGX N/A
- Revenue Next Year
- OKE $2.22
- TNGX N/A
- P/E Ratio
- OKE $15.97
- TNGX N/A
- Revenue Growth
- OKE 39.15
- TNGX 10.09
- 52 Week Low
- OKE $75.48
- TNGX $1.03
- 52 Week High
- OKE $118.07
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- OKE 48.46
- TNGX 74.27
- Support Level
- OKE $79.18
- TNGX $5.34
- Resistance Level
- OKE $82.79
- TNGX $5.63
- Average True Range (ATR)
- OKE 1.69
- TNGX 0.50
- MACD
- OKE 0.11
- TNGX -0.04
- Stochastic Oscillator
- OKE 53.10
- TNGX 84.15
About OKE ONEOK Inc.
Oneok is a diversified midstream service provider specializing in natural gas gathering, processing, storage, and transportation and natural gas liquids transportation and fractionation. It also operates a refined product and crude oil segment connecting producers, refiners, and consumers. Operations are in the midcontinent, Permian, and Rocky Mountain regions.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.